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Abstract
Background: X-linked Charcot-Marie Tooth (CMT) is caused by mutations in the connexin32
gene that encodes a polypeptide which is arranged in hexameric array and form gap junctions.
Methods: We describe two novel mutations in the connexin32 gene in two Norwegian families.
Results: Family 1 had a c.225delG (R75fsX83) which causes a frameshift and premature stop
codon at position 247. This probably results in a shorter non-functional protein structure. Affected
individuals had an early age at onset usually in the first decade. The symptoms were more severe
in men than women. All had severe muscle weakness in the legs. Several abortions were observed
in this family. Family 2 had a c.536 G>A (C179Y) transition which causes a change of the highly
conserved cysteine residue, i.e. disruption of at least one of three disulfide bridges. The mean age
at onset was in the first decade. Muscle wasting was severe and correlated with muscle weakness
in legs. The men and one woman also had symptom from their hands.
The neuropathy is demyelinating and the nerve conduction velocities were in the intermediate
range (25–49 m/s). Affected individuals had symmetrical clinical findings, while the neurophysiology
revealed minor asymmetrical findings in nerve conduction velocity in 6 of 10 affected individuals.
Conclusion: The two novel mutations in the connexin32 gene are more severe than the majority
of previously described mutations possibly due to the severe structural change of the gap junction
they encode.
Background
Charcot-Marie-Tooth (CMT) disease is the most common
inherited disorder of the peripheral nervous system with
an estimated prevalence of 1 in 2,500 [1]. It is clinically,
neurophysiologically and genetically a heterogeneous dis-
order. Clinical features are distal muscle wasting and
weakness, sensory loss with reduced tendon reflexes and
foot deformities [2,3]. Neurophysiology can classify CMT
into type 1 and 2, depending on whether the motor con-
duction velocity (MCV) is less or above 38 m/s [4]. A third
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autosomal dominant, autosomal recessive or X-linked
disorder [6]. It has been estimated that autosomal domi-
nant inheritance accounts for 88%, X-linked for 9% and
autosomal recessive for 3% of the inherited forms of CMT
[1]. The majority of CMT cases are caused by a duplication
of peripheral myelin protein 22 (PMP22), which is carried
by 71% of those with CMT 1 [7]. X-linked CMT caused by
mutations in the connexin32 gene (GJB1) is probably the
2nd most frequent cause of CMT [8]. In humans there are
at least 20 different connexin genes [9]. The polypeptides
encoded by a connexin gene are arranged in hexameric
array and form gap junctions [10]. Gap junctions contain
hydrophilic membrane channels that allow direct com-
munication between neighboring cells through the diffu-
sion of ions, metabolites and small signaling molecules
[11]. Mutations in connexin genes can beside CMT cause
the skin disorders Vohwinkel syndrome and erythrokera-
toderma variabilis, cardiovascular disorders, cataract and
deafness [12-17]. Connexin32 is expressed in both the
peripheral and central nervous system (PNS and CNS). It
is expressed in the paranodal region and incisures of mye-
linating Schwann cells, and in cell bodies and processes of
oligodendrocytes, while it is not expressed in the compact
myelin layer [18]. This is interesting since some patients
with mutations in the connexin32 gene have hearing loss,
subclinical CNS symptoms, acute or chronic clinical CNS
manifestations as well as CNS involvement on brain MRI
[19-22].
We present two novel mutations in the Connexin32 gene
and the clinical features in the two families.
Methods
Patients
Families from Norway with possible X-linked Charcot-
Marie-Tooth disease were analyzed for mutations in the
connexin32 gene. The two families were from west and
southeast of Norway.
Examination
Affected and unaffected family members available were
interviewed and clinically examined by geneticist and
neurologist GJB. Information on III-1, III-2, III-3, III-4, III-
6, IV-1, IV-2, IV-3, IV-5, IV-6, VI-1 and VI-2 from family 1
was derived from the proband, IV-8 (Fig. 1A). In family 2
information on II-2, II-4 and II-5, the latter representing 3
unaffected siblings whom had no affected children was
based on the proband, IV-1 and his mother III-2 (Fig. 1B).
The interview was semi-structured and the participants
received a thorough genetic and neurological examina-
tion. All findings were recorded in an evaluated Norwe-
gian scheme designed for neuropathy with additional
items added by GJB [23-25].
Neurophysiology
GJB conducted the majority of the neurophysiological
examinations. The patients were acclimatized to room
temperature 25°C prior to the neurophysiological exami-
nation. Standard techniques with surface electrodes were
used for antidromic sensory conduction and orthodromic
motor conduction. Needle electrodes were used, if the sur-
face electrodes failed to record conduction velocities of
the sural nerve. In general both the right and left sural,
superficial peroneal and tibial nerves were examined and
some had their median nerves examined too. Electromy-
ography (EMG) was performed in left leg muscles; abduc-
tor hallucis, extensor digitorum brevis, peroneus longus,
tibialis anterior and posterior, and gastrocnemius. Only
gene carriers had a neurophysiological examination once.
Genetics
DNA was extracted from leucocytes using QIAgen Flexi-
Gene kit. The coding region of the connexin32 gene was
amplified using Invitrogen Platinum taq polymerase
Cat.Nos 10966-026 and 2 mM MgCl2. Primers used was
forward AATGAGGCAGGATGAACTGG and reverse CCT-
GGTATGTGGCATCAGC spanning the exon 2 creating an
877 bp band. Annealing temperature was 63°C and
number of cycles was 35. The sequencing was carried out
using internal forward primer TGCTCTACCCT-
GGCTATGC starting at base 589 and reverse primer CCA-
CATTGAGGATGATGCAG starting at base 745 and in
some cases reverse primer GCCATGCACGTGGCTCAC-
CAGCAA starting at base 297 in addition to the PCR prim-
ers and BigDye Terminator kit version 1.1 Applied
Biosystems. Sequences were analyzed on an ABI3100
automated DNA sequencer (Applied Biosystems). Num-
bering of nucleotides is according to the open reading
frame of the cDNA sequence, GenBank accession
NM_000166s[26].
The karyotype was analyzed using standard G-band tech-
nique of the chromosomes.
Ethics
The study was approved by the Regional Committees for
Medical Research Ethics.
The patients gave written consent for participating in the
study.
Results
Fig. 1 and 2 show two pedigrees with novel mutations in
connexin32. Family 1 had a c.225delG (R75fsX83) which
causes a frameshift and premature stop codon at position
247. The original sequence from amino acid 76 was
changed from LWSLQLILV.. to CGPCSSSX. Family 2 had
a c.536G>A (C179Y) transition which causes a change of
cysteine to tyrosine at position 179.Page 2 of 9
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This pedigree is compatible with X-linked inheritance. III-
2 is shown as an unaffected individual, since the only
information we have is that she had had a transient psy-
chiatric problem during teenage. She also had psychiatric
problems and later committed suicide. Affected female
descendants of II-2 and II-3 have only female descendants
and spontaneous abortions of unknown gender as well as
a stillborn daughter (IV-11), while unaffected females
have descendants of both gender.
Family 2
This pedigree is compatible with X-linked inheritance,
although I-2 is shown as an unaffected individual, since
we had no information about her. V-1 carries the muta-
tion, but was unaffected at age 8 years.
Age at onset
Women had a mean age at onset at 8.3 years (range 1–22),
and men had a mean age at onset at 6 years (range 3–11).
Table 1 shows that the first symptoms usually were muscle
cramps and weakness, but problems skiing and skating
were also often encountered as the first symptom.
Clinical characteristics
Table 2 and Table 3 show the clinical characteristics of
CMT. Men were more severely affected than women, and
also had a faster disease progression.
Motor symptoms
Muscle wasting was correlated with muscle weakness and
the symptoms were symmetrical. All men had severe mus-
cle weakness in their legs and hands, while only one
woman had marked symptoms from her hands.
Sensory symptoms
Affected men and three affected women had reduced pain
sensation. Sense of vibration was reduced in all but one.
Sensation of proprioception and touch was generally pre-
served.
Tendon reflexes
The Achilles reflex was reduced or absent in all affected
individuals, while two women and all affected men had
reduced or absent reflexes in the upper extremities.
shows a pedigree with novel mutations in connexin32Figure 1
shows a pedigree with novel mutations in connexin32. III-7, IV-4, IV-8, IV-12, IV-15 had the mutation c.225delG 
(R75fsX83) while IV-10, IV-14 and V-6 did not have the deletion.
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eformities
The majority had hammertoes and pes cavus, while two
men also had excavated palms.
Ataxia
One man had ataxia.
Balance
Balance problems were experienced by the majority and
this symptom was more pronounced in family 2 than in
family 1.
Neurophysiological and neuroradiological investigations
Table 4 shows the neurophysiological findings. The
amplitudes and distal motor latencies were in accordance
with the delayed conduction velocities. Both motor and
sensory nerve conduction velocities were reduced or not
obtainable in both the lower and upper extremities. The
seven years old girl (family 2, V 2) had asymmetrical
CMAP amplitudes and motor conduction velocities in the
low-normal range in the lower extremities. The conduc-
tion velocities were more reduced in men than in women.
The majority of conduction velocities were symmetrical,
but most of the affected family members had one asym-
metrical finding. All EMG findings were consistent with
peripheral neuropathy except in the seven years old girl. A
man had a visual evoked potentials (VEP) investigation
showing severe delayed latency on both sides, while a
magnetic resonance imaging (MRI) of his brain taken
some years later was normal. He had no visual distur-
bances.
Discussion
Our main finding is the identification of two novel muta-
tions in connexin32. Family 1 had a c.225delG
(R75fsX83) which cause a frameshift and a premature
stop at position 247. This causes an altered transmem-
brane (M2) portion and a shortened polypeptide which is
lacking two of the four transmembrane domains (M3 and
M4), an extracellular loop (E2), the intracellular loop and
the C-terminal end [27]. The exact mechanism of
connexin32 channel assembly is not known to our knowl-
edge. We hypothesize that the polypeptide encoded by the
mutated connexin32 gene result in a polypeptide which is
not arranged in a hexameric array due to the change in
protein structure. Connexin32 is expressed in early
human placenta as well as placenta tissue culture [28,29].
The human placenta differs from other somatic tissues,
since it has an ability to reverse the X-inactivation pro-
gram [30]. Thus, it is likely that female fetuses with the
connexin32 mutation will have only normal connexin32
gap junction in the placenta, while male fetuses with the
mutation will lack connexin32 gap junctions. Family 1 is
characterized by at least four spontaneous abortions. We
could not explain this by chromosome abnormalities as
III-7 has a normal female karyotype 46,XX. Other etiolo-
Table 1: First symptom of Charcot-Marie-Tooth disease.
Family 
member
Sex Age at 
onset 
years
First symptom
Family 1
III-7  6 Muscle cramps, thin legs, problems 
going skiing and skating
IV-4  3 Muscle cramps, problems with 
running and reduced balance
IV-8  10 Problems with running and skating 
and reduced balance
IV-12  6 Problems with running and 
excessive falling
IV-15  22 Excessive tiredness
V-4  7 Problems with running and skiing
Family 2
III-2  6 Muscle cramps, problems with 
running and reduced balance
IV-1  4 Weakness in lower extremities, 
problems with running and walking 
and reduced balance
IV-3  11 Weakness in lower extremities, 
problems with running and walking 
and reduced balance
V-1  1 Reduced balance and problems 
with walking
shows a pedigree with novel mutations in connexin32Figure 2
shows a pedigree with novel mutations in connexin32. III-2, 
IV-1, IV-3, V-1 and V-2 had the mutation c.536G>A (C179Y) 
while IV-2 and IV-4 did not have the G→A transition.
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Table 2: Clinical characteristics of Charcot-Marie-Tooth scored according to Neuropathy Impairment score (NIS) unless otherwise 
indicated.
Family 1 Family 2
Family member III-7 IV-4 IV-8 IV-12 IV-15 V-4 III-21 IV-1 IV-3 V-2
Sex          
Age at onset 6 3 10 6 22 7 6 4 11 1
Disease duration 62 41 36 30 7 13 51 33 25 6
Clinical characteristics
Muscle wastingNIS
Underarm 1 1 1 1 0 1 0 2 1 0
Hand 1 2 2 1 0 1 1 2 2 1
Thigh 1 1 0 1 0 0 0 1 0 0
Leg 1 2 2 2 0 2 1 2 2 0
Feet 1 2 2 2 1 2 2 2 2 0
Muscle weaknessNIS
Elbow flexion 0 0,5 0 0 0 0 1 0 0 0
Hand flexion 0 0,5 0 0 0 0 0 0,5 1 0
Hand extension 0 0,5 0 0 0 0 0 0,5 0 0
Finger flexion 0,5 1 0,5 0,5 0 0 0 0,5 0 0
Finger spreading 0,5 1 0,5 0,5 0 0,5 0,5 1,5 2 0
Thumb, abduction 0,5 2 1 0,5 0 0,5 0,5 5 2 0
Knee flexion 0 0 0 0 0 0 0 0,5 0 0
Ankle dorsi-Flexion 0,5 2 1 1/0,52 0 0,5 0,5 2 3 0
Ankle plantar-
Flexion
0 1,5 0,5 1 0 0 0 2 1,5 0
Toe extensor 1 2 1 1,5 0,5 1 0,5 2 3 0
Toe flexor 1 2 0,5 0,5 0 0,5 0,5 2 1,5 0
Sensory loss
Touch3
Thigh 0 0 0 0 0 0 1 0 0 0
Feet, leg 0 0 0 0 0 0 1 0 0 0
Pain3
Hand, underarm 0 1 0/12 1 0 0 1 1 1 0
Thigh 0 1 0 1 0 0 1 1 0 0
Feet, leg 0 1 1 1 0 0 2 2 1 0
Vibration3
Hand 0 1 1 0 0 0 2 2 1 0
Knee 1 2 1 1 0 0 2 2 1 0
Ankle 2 2 2 2 1 0 2 2 1 0
1. metatarsal 2 2 2 2 2 2 2 2 2 0
1. toe 2 2 2 2 2 2 2 2 2 0
ProprioceptiveNIS
Toe 0 2 0 0 0 0 1/02 0 0 0
ReflexesNIS
Biceps 0 1 0 2 0 0 0 2 2 1
Triceps 0 0 0 1 0 0 0 1 0 0
Brachioradialis 0 1 0 1 0 0 0 1 0 0
Patellar 0 1 0 2 0 1 1 2 2 1
Achilles 2 2 2 2 2 2 1 2 2 1
Deformities3
Excavated palms 0 0 0 0 0 0 0 2 1 0
Pes cavus 1 2 2 0 1 2 1 2 2 0
Hammertoes 1 2 2 1 0 1 1 0 2 0
Syndactyly 0 0 0 0 0 0 0 0 1 0
Kyphoscoliosis 0 1 0 0 0 1 0 0 0 0
Ataxia in legs3 0 0 0 0 0 0 0 1 0 0
Romberg3 1 1 1 1 0 0 0 2 2 1
1She had a right cerebral infarction at age 52 years and a slight spasticity of the left arm as sequelae.
2Asymmetrical signs right/left.
30 = normal; 1 = mild/moderate affected modality; 2 = severe affected modality.
BMC Neurology 2007, 7:19 http://www.biomedcentral.com/1471-2377/7/19gies to recurrent spontaneous abortions are anatomical,
endocrine, placenta abnormalities, infection, smoking
and alcohol consumption, other environmental factor,
psychological trauma and stressful life event, certain coag-
ulation and immunoregulatory protein defects [31]. We
have no knowledge that any of these causes are of signifi-
cance in this family. However, increased rate of abortions
has not been described in other CMTX families. Further-
more connexin26 and connexin43 are expressed in the
placenta, and may compensate for the possible loss of
connexin32 function [32]. III-7 and IV-8 have seven
female and no male offspring an incidence that happens
by chance in 1/128. We have no explanation for the spon-
taneous abortions in this family.
Family 2 had a point mutation in the connexin32 gene,
c.536G>A (C179Y). This mutation causes an amino acid
change from cysteine to tyrosine at position 179, which is
the last cysteine residue in the E2 loop. The E1 and E2
loops each have three highly conserved cysteine residues
[27]. Thus, the number of disulfide-bridges stabilizing the
loops between two hemi-channels from two opposed cell
are reduced, which alter the function of the connexin32
gap junction. One man had ataxia in the lower extremi-
ties. This is likely to be a symptom of peripheral nature
due to the sensory disturbances although a central origin
can not be excluded. Balance problems were prominent in
both families irrespective of disease duration and disease
severity, while the neurological examination revealed nor-
mal proprioception in nearly all affected individuals.
Thus, balance problems might represent a CNS symptom,
since balance is based on vision, proprioception and equi-
librium. The literature describes central symptoms such as
deafness, extensor plantar response, transient ataxia, dys-
arthria, dysphagia or weakness as well as abnormal VEP,
brainstem auditory evoked potentials and central motor
evoked potentials [22,33-35]. Brain MRI shows transient,
recurrent, white matter lesions in X-linked Charcot-Marie-
Tooth disease [33,34]. One man had pathological visual
evoked potential (VEP) with delayed latency on both
sides, but a normal MRI of the brain taken some years
later. All affected individuals carried the mutation and
unaffected individuals did not carry it with one exception.
An obligate gene carrier had the mutation (family 2, V-1),
but was clinically asymptomatic at age 8 years, while she
had reduced CMAP neurophysiologically. We defined age
at onset as the first recorded clinical symptom that could
be ascribed to CMT. The mean age at onset was in the first
decade in both families. The mean age at onset was 4–12
years lower in men and 9–11 year lower in women than
previously reported in X-linked CMT [36,37]. The mean
age at onset in women will of course increase depending
on the age at onset in the asymptomatic obligate gene car-
rier (family 2, V-1). Since eight women carried the gene,
each 8 year period will increase the mean age at onset one
year in women. Onset before 10 years was encountered in
27% of male and 15% of female in a study of 93 patients
with X-linked CMT from 37 different families with 27 dif-
ferent connexin32 mutations [36]. Thus, the two novel
mutations cause an earlier disease onset than the majority
of the previously described connexin32 gene mutations.
The literature reports of very early onset of X-linked CMT
in a 15 months old girl with severe symptoms [36]. Our
patient (family 2, V-2) had less severe symptoms with age
Table 3: Neuropathy Impairment Score (NIS) of the Charcot-Marie-Tooth patients in the two families. 
Family 1 Family 2
Family member III-7 IV-4 IV-8 IV-12 IV-15 V-4 III-2 IV-1 IV-3 V-2
Sex          
Age at onset 6 3 10 6 22 7 6 4 11 1
Disease duration 62 41 36 30 7 13 51 33 25 6
NIS
Sum cranial nerves 0 0,5 0 0 0 0 0 0 0 0
Muscle weakness
MRC-sumscore1 1 5 2 2 0 1 3 5 8 0
Sum UE2 3 10 4 3 0 2 4 16 10 0
Sum LE3 5 15 6 7,5 1 4 3 17 18 0
Sum muscle weakness4 8 25 10 10,5 1 6 7 33 28 0
Sum reflex deficit 2 10 4 16 4 6 2 16 12 6
Sum sensory deficit 4 14 6 8 4 4 15 14 10 0
Total sum NIS5 14 49,5 20 34,5 9 16 24 63 50 6
1MRC sum score; 6 muscles on both sides, 3 muscle upper extremity (UE) and 3 muscles lower extremity (LE) respectively.
2Sum UE 9 muscles R and L.
3Sum LE 8 muscles R and L.
4Sum muscle weakness 19 muscles.
5Total sum NIS: The score consists of Sum cranial nerves, Sum muscle weakness, Sum reflex deficit and Sum sensory deficitPage 6 of 9
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Table 4: Electroneurographical findings in affected, gray shading indicate men. Sensory nerve action potential (SNAP) (µV), compound muscle action potential (CMAP) (mV)
Family 
member
Sex Age at 
onset (yr)
Age at 
examination 
(yr)
Sensory Sural 
nerve
Motor Peroneal nerve Motor Tibial nerve Sensory Median 
nerve
Motor Median nerve EMG Chronic 
denervation
SNAP CV CMAP CV CMAP CV SNAP CV CMAP/ CV
Family 1 R L R L R L R L R L R L R L R L R L R L
III-7  6 68 - - - - 3.3 1.7 43.8 37.0 - - - - Present
IV-4  3 44 - - - - - - - - - - - - 33.5 36.6 Present
IV-8  10 46 - - - - 1 0.2 32.8 25.4 0.8 1.7 30.2 31.1 - - - - 1.0 0.3 36.8 34.6 Present
IV-12  6 36 - 0.6 - 30.4 - - - - 1.2 1.3 25.2 25.0 Present
IV-15  22 29 - - - - 5.5 4.0 39.5 41.9 4.0 5.8 44.1 46.9 Slightly
V-4  7 20 - - 29.3 - - 31.8 31.7 - - 29.7 32.5 Present
Family 2
III-2  6 44 - - 1.5 29.0 0.5 30.0 2.5 44.0 Present
IV-1  4 37 - - - - - - - - - - - - - - - - 0.3 0.2 25.8 22.7 Present
IV-3  11 18 31.0 - - 30.0
*
Present
V-1  8 3
.
8
5
7
,
8
0.8 1.3 45.9 45.8 Not present
V-2  1 7 1
.
0
4
8
.
3
2.0 1.3 48.8 46.7 Not present
- not recordable
* ulnar nerve
BMC Neurology 2007, 7:19 http://www.biomedcentral.com/1471-2377/7/19at onset at 16 months. Men had in general more severe
and faster disease progression than women, in accordance
with the literature [4,22,36,38,39].
The neurophysiological examinations of affected individ-
uals were compatible with intermediate type of CMT (25–
49 m/s). Affected individuals had symmetrical clinical
findings, while the neurophysiological examination
revealed minor asymmetrical results in nerve conduction
velocities. However, we only conducted the neurophysio-
logical examination once, so the data are not reproduced.
This is likely to be a real phenomenon, since the ampli-
tudes and distal latencies (not shown in table 3) showed
variation in accordance with the nerve conduction veloci-
ties. Neither X-inactivation alone nor the specific muta-
tions can explain the asymmetry as it occurred in both
men and women and in both families. Asymmetries in
motor conduction velocities have also been reported by
others [40,41]. Otherwise the neurophysiological find-
ings were similar to those of five other studies of X-linked
CMT [4,22,36,38,39].
Conclusion
We conclude that the two novel mutations in the
connexin32 gene have an earlier onset than the majority
of previously described mutations.
Competing interests
The author(s) declare that they have no competing inter-
est.
Authors' contributions
GJB acquired the material, conceived the study, partici-
pated in the design of the study and drafted the manu-
script. JCS carried out the molecular genetic studies and
the sequence alignment. GB participated in the design of
the study and helped to draft the manuscript. MBR con-
ceived the study, participated in the design of the study
and drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The study was financially supported by the University of Oslo, Faculty Divi-
sion Akershus University Hospital, Helse ∅st, Sentralsykehuset i Akershus 
and the Nansen Foundation.
References
1. Skre H: Genetic and clinical aspects of Charcot-Marie-Tooth's
disease.  Clin Genet 1974, 6:98-118.
2. Charcot JM, Marie P: Sur une form particulière d'atrophie mus-
culaire progressive, souvant familiale, debutant par les pieds
et les jambes, et atteignant plus tard les mains.  Rev Méd (Paris)
1886, 6:97-138.
3. Tooth HH: The Peroneal Type of Progressive Muscular Atro-
phy.  London: H. K. Lewis; 1886. 
4. Harding AE, Thomas PK: The clinical features of hereditary
motor and sensory neuropathy types I and II.  Brain 1980,
103:259-280.
5. Nicholson G, Nash J: Intermediate nerve conduction velocities
define X-linked Charcot-Marie-Tooth neuropathy families.
Neurology 1993, 43:2558-2564.
6. OMIM™ – online Mendelian inheritance in man   [http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=omim]
7. Nelis E, Van Broeckhoven C, De Jonghe P, Lofgren A, Vandenberghe
A, Latour P, Le Guern E, Brice A, Mostacciuolo ML, Schiavon F, Palau
F, Bort S, Upadhyaya M, Rocchi M, Archidiacono N, Mandich P, Bel-
lone E, Silander K, Savontaus ML, Navon R, Goldberg-Stern H, Estivill
X, Volpini V, Friedl W, Gal A: Estimation of the mutation fre-
quencies in Charcot-Marie-Tooth disease type 1 and heredi-
tary neuropathy with liability to pressure palsies: a European
collaborative study.  Eur J Hum Genet 1996, 4:25-33.
8. Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ, Paul DL, Chen
K, Lensch MW, Chance PF, Fischbeck KH, et al.: Connexin muta-
tions in X-linked Charcot-Marie-Tooth disease.  Science 1993,
262:2039-2042.
9. Willecke K, Eiberger J, Degen J, Eckardt D, Romualdi A, Guldenagel
M, Deutsch U, Sohl G: Structural and functional diversity of
connexin genes in the mouse and human genome.  Biol Chem
2002, 383:725-737.
10. Musil LS, Goodenough DA: Multisubunit assembly of an integral
plasma membrane channel protein, gap junction
connexin43, occurs after exit from the ER.  Cell 1993,
74:1065-1077.
11. Richard G, White TW, Smith LE, Bailey RA, Compton JG, Paul DL,
Bale SJ: Functional defects of Cx26 resulting from a hetero-
zygous missense mutation in a family with dominant deaf-
mutism and palmoplantar keratoderma.  Hum Genet 1998,
103:393-399.
12. Maestrini E, Korge BP, Ocana-Sierra J, Calzolari E, Cambiaghi S, Scud-
der PM, Hovnanian A, Monaco AP, Munro CS: A missense muta-
tion in connexin26, D66H, causes mutilating keratoderma
with sensorineural deafness (Vohwinkel's syndrome) in
three unrelated families.  Hum Mol Genet 1999, 8:1237-1243.
13. Severs NJ: Pathophysiology of gap junctions in heart disease.
J Cardiovasc Electrophysiol 1994, 5:462-475.
14. Rummery NM, Hill CE: Vascular gap junctions and implications
for hypertension.  Clin Exp Pharmacol Physiol 2004, 31:659-667.
15. Sohl G, Willecke K: Gap junctions and the connexin protein
family.  Cardiovasc Res 2004, 62:228-232.
16. Berry V, Mackay D, Khaliq S, Francis PJ, Hameed A, Anwar K, Mehdi
SQ, Newbold RJ, Ionides A, Shiels A, Moore T, Bhattacharya SS: Con-
nexin 50 mutation in a family with congenital "zonular
nuclear" pulverulent cataract of Pakistani origin.  Hum Genet
1999, 105:168-170.
17. Mackay D, Ionides A, Kibar Z, Rouleau G, Berry V, Moore A, Shiels
A, Bhattacharya S: Connexin46 mutations in autosomal domi-
nant congenital cataract.  Am J Hum Genet 1999, 64:1357-1364.
18. Scherer SS, Deschenes SM, Xu YT, Grinspan JB, Fischbeck KH, Paul
DL: Connexin32 is a myelin-related protein in the PNS and
CNS.  J Neurosci 1995, 15:8281-8294.
19. Bahr M, Andres F, Timmerman V, Nelis ME, Van Broeckhoven C,
Dichgans J: Central visual, acoustic, and motor pathway
involvement in a Charcot-Marie-Tooth family with an
Asn205Ser mutation in the connexin 32 gene.  J Neurol Neuro-
surg Psychiatry 1999, 66:202-206.
20. Panas M, Kalfakis N, Karadimas C, Vassilopoulos D: Episodes of
generalized weakness in two sibs with the C164T mutation
of the connexin 32 gene.  Neurology 2001, 57:1906-1908.
21. Stojkovic T, Latour P, Viet G, de Seze J, Hurtevent JF, Vandenberghe
A, Vermersch P: Vocal cord and diaphragm paralysis, as clinical
features of a French family with autosomal recessive Char-
cot-Marie-Tooth disease, associated with a new mutation in
the GDAP1 gene.  Neuromuscul Disord 2004, 14:261-264.
22. Lee MJ, Nelson I, Houlden H, Sweeney MG, Hilton-Jones D, Blake J,
Wood NW, Reilly MM: Six novel connexin32 (GJB1) mutations
in X-linked Charcot-Marie-Tooth disease.  J Neurol Neurosurg
Psychiatry 2002, 73:304-306.
23. Skre H: Hereditary ataxias and their associated traits. A clin-
ical, genetic, and epidemiological study in Western Norway.
In PhD thesis University of Bergen, Department of Neurology and Uni-
versity of Oslo, Institute of Medical Genetics; 1976. 
24. Skre H: Neurological signs in a normal population.  Acta Neurol
Scand 1972, 48:575-606.Page 8 of 9
(page number not for citation purposes)
BMC Neurology 2007, 7:19 http://www.biomedcentral.com/1471-2377/7/19Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
25. Skre H: Application of a quantitative scoring system in the
investigation of some hereditary neurological disorders.  Clin
Genet 1974, 5:163-172.
26. den Dunnen JT, Antonarakis SE: Nomenclature for the descrip-
tion of human sequence variations.  Hum Genet 2001,
109:121-124.
27. Kumar NN, Gilula NB: The gap junction communication chan-
nel.  Cell 1996, 84:381-388.
28. Nishimura T, Dunk C, Lu Y, Feng X, Gellhaus A, Winterhager E, Ros-
sant J, Lye SJ: Gap junctions are required for trophoblast pro-
liferation in early human placental development.  Placenta
2004, 25:595-607.
29. Cronier L, Defamie N, Dupays L, Theveniau-Ruissy M, Goffin F,
Pointis G, Malassine A: Connexin expression and gap junctional
intercellular communication in human first trimester tro-
phoblast.  Mol Hum Reprod 2002, 8:1005-1013.
30. Migeon BR, Axelman J, Jeppesen P: Differential X reactivation in
human placental cells: implications for reversal of X inactiva-
tion.  Am J Hum Genet 2005, 77:355-364.
31. Pandey MK, Rani R, Agrawal S: An update in recurrent spontane-
ous abortion.  Arch Gynecol Obstet 2005, 272:95-108.
32. Pfarrer CD, Heeb C, Leiser R: Expression of gap junctional con-
nexins 26, 32 and 43 in bovine placentomes during preg-
nancy.  Placenta 2006, 27:79-86.
33. Paulson HL, Garbern JY, Hoban TF, Krajewski KM, Lewis RA, Fisch-
beck KH, Grossman RI, Lenkinski R, Kamholz JA, Shy ME: Transient
central nervous system white matter abnormality in X-
linked Charcot-Marie-Tooth disease.  Ann Neurol 2002,
52:429-434.
34. Hanemann CO, Bergmann C, Senderek J, Zerres K, Sperfeld AD:
Transient, recurrent, white matter lesions in X-linked Char-
cot-Marie-Tooth disease with novel connexin 32 mutation.
Arch Neurol 2003, 60:605-609.
35. Bähr M, Andres F, Timmerman V, Nelis ME, Van Broeckhoven C,
Dichgans J: Central visual, acoustic, and motor pathway
involvement in a Charcot-Marie-Tooth family with an
Asn205Ser mutation in the connexin 32 gene.  J Neurol Neuro-
surg Psychiatry 1999, 66:202-206.
36. Dubourg O, Tardieu S, Birouk N, Gouider R, Leger JM, Maisonobe T,
Brice A, Bouche P, LeGuern E: Clinical, electrophysiological and
molecular genetic characteristics of 93 patients with X-
linked Charcot-Marie-Tooth disease.  Brain 2001,
124:1958-1967.
37. Lin GS, Glass JD, Shumas S, Scherer SS, Fischbeck KH: A unique
mutation in connexin32 associated with severe, early onset
CMTX in a heterozygous female.  Ann N Y Acad Sci 1999,
883:481-484.
38. Birouk N, LeGuern E, Maisonobe T, Rouger H, Gouider R, Tardieu S,
Gugenheim M, Routon MC, Leger JM, Agid Y, Brice A, Bouche P: X-
linked Charcot-Marie-Tooth disease with connexin 32 muta-
tions: clinical and electrophysiologic study.  Neurology 1998,
50:1074-1082.
39. Hahn AF, Bolton CF, White CM, Brown WF, Tuuha SE, Tan CC, Ains-
worth PJ: Genotype/phenotype correlations in X-linked dom-
inant Charcot-Marie-Tooth disease.  Ann N Y Acad Sci 1999,
883:366-382.
40. Gutierrez A, England JD, Sumner AJ, Ferer S, Warner LE, Lupski JR,
Garcia CA: Unusual electrophysiological findings in X-linked
dominant Charcot-Marie-Tooth disease.  Muscle Nerve 2000,
23:182-188.
41. Lewis RA, Sumner AJ, Shy ME: Electrophysiological features of
inherited demyelinating neuropathies: A reappraisal in the
era of molecular diagnosis.  Muscle Nerve 2000, 23:1472-1487.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2377/7/19/prepubPage 9 of 9
(page number not for citation purposes)
